Abstracts

STATEWIDE TRENDS OF ACQUIRED HIV-1 DRUG RESISTANCE IN RHODE ISLAND: 2004-2021

Background: HIV-1 acquired drug resistance (ADR) may compromise sustainable antiretroviral therapy (ART)effectiveness and efforts toward ending the HIV epidemic. However, comprehensive and longitudinaldata on ADR, and its current extent and impact on ART options and newer medications are limited andcan inform care. Methods: We aggregated all available HIV-1 protease-reverse-transcriptase-integrase sequences from ART-experienced persons in care…

COGNITIVE, MOTOR, & NEGATIVE VALENCE SYSTEMS IN NEUROLOGIC PASC: A PRELIMINARY STUDY

Background: Nervous system post-acute sequelae of COVID-19 (NS-PASC) include cognitive and mental health symptoms. To further define these, we applied a Research Domain Criteria (RDoC) approach to examine motor, positive valence (PV) and negative valence (NV) systems, and social processing data in The COVID Mind Study of NS-PASC. Methods: NS-PASC participants (>3 months after COVID-19)…

PHASE 1 TRIAL OF CAP256V2LS AND VRC07-523LS ANTIBODIES AMONG WOMEN IN SOUTH AFRICA

Background: Young women in sub-Saharan Africa continue to bear a high burden of HIV infection. Combination anti-HIV monoclonal antibodies are a potential HIV prevention technology that may overcome adherence challenges of daily oral pre-exposure prophylaxis. CAPRISA 012B, a first-in-human dose-escalation phase 1 trial evaluated the safety, pharmacokinetics and neutralization activity of the monoclonal antibody CAP256V2LS…

IRON METABOLISM IN CHRONIC HIV: IMPAIRED HEPCIDIN-SOLUBLE TRANSFERRIN RECEPTOR AXIS

Background: Chronic HIV-infected subjects under effective antiretroviral treatment (ART) exhibit an immune dysfunction leading to comorbidities. Since iron metabolism plays an essential role in immune cell function, its regulation may be relevant in this context. Methods: We included 92 asymptomatic chronic HIV-infected subjects under suppressive treatment (HIV), 25 age-matched non-HIV healthy donors (< 65 years…

VIRAL DYNAMIC MODELS PROVIDE AN EXPLANATION FOR SARS-CoV-2 REBOUND AFTER NIRMATRELVIR

Background: . A 5-day course of nirmatrelvir-ritonavir (N/R) can significantly reduce the hospitalization and death rates and the duration of infectiousness in high-risk SARS-CoV-2 patients. However, in a fraction of treated individuals virus rebounds following an initial recovery after treatment. The mechanism driving rebound is not well understood. We hypothesize that treatment with N/R near…

LONG-ACTING NANOFORMULATIONS REDUCE DOLUTEGRAVIR EXPOSURE TO EMBRYO BRAIN

Background: Dolutegravir (DTG) is an integrase strand transfer inhibitor, which is currently recommended as part of first-line treatment regimens for HIV-1 patients worldwide. This is particularly due to its high potency, limited drug-drug interactions and intrinsic high genetic barrier to resistance. Nonetheless, concerns emerged for its usage in pregnant women. Notably, DTG-based regimens have been…